

EQA round: APLA2/21 - Antiphospholipid Antibodies

Deadline: 01.10.2021

Key:	>>> ... marks correct (expected) result	N ... number of the results
	> ... marks conditionally correct (acceptable) result	Nrel ... relative number of the results
	± ... marks the result not evaluated	

Test

Sample	Group		N	Result	N _{rel}
(461) anti-cardiolipin screening					
A	(38) IL	>>>	1	Negative	6,3 %
	(135) OrgenTec	>>>	12	Negative	75 %
	(148) Aesku.lab Diagnostika	>>>	3	Negative	19 %
----- Total per sample: n = 16		----- Success: 100 %			
B	(38) IL	>>>	1	Positive	6,3 %
	(135) OrgenTec	>>>	12	Positive	75 %
	(148) Aesku.lab Diagnostika	>>>	3	Positive	19 %
----- Total per sample: n = 16		----- Success: 100 %			
Total success: 100 %					

(463) anti-cardiolipin IgG

A	(5) Dialab	>>>	1	Negative	1,7 %
	(14) Bio-Rad	>>>	1	Negative	1,7 %
	(38) IL	>>>	3	Negative	5,0 %
	(49) BioVendor	>>>	1	Negative	1,7 %
	(87) Euroimmun	>>>	6	Negative	10 %
	(115) BioSystems	>>>	1	Negative	1,7 %
	(135) OrgenTec	>>>	22	Negative	37 %
	(139) BL Diagnostics	>>>	1	Negative	1,7 %
	(148) Aesku.lab Diagnostika	>>>	7	Negative	12 %
	(166) Thermo Fisher	>>>	4	Negative	6,7 %
	(183) Immunodiagnostic Systems	>>>	2	Negative	3,3 %
	(211) INOVA Diagnostics	>>>	9	Negative	15 %
	(999) another manufacturer	>>>	2	Negative	3,3 %
----- Total per sample: n = 60		----- Success: 100 %			
B	(5) Dialab	>>>	1	Positive	1,7 %
	(14) Bio-Rad	>>>	1	Positive	1,7 %
	(38) IL	>>>	3	Positive	5,0 %
	(49) BioVendor	>>>	1	Positive	1,7 %
	(87) Euroimmun	>>>	6	Positive	10 %
	(115) BioSystems	>>>	1	Positive	1,7 %
	(135) OrgenTec	>>>	22	Positive	37 %
	(139) BL Diagnostics	>>>	1	Positive	1,7 %
	(148) Aesku.lab Diagnostika	>>>	7	Positive	12 %
	(166) Thermo Fisher	>>>	4	Positive	6,7 %
	(183) Immunodiagnostic Systems	>>>	2	Positive	3,3 %
	(211) INOVA Diagnostics	>>>	9	Positive	15 %
	(999) another manufacturer	>>>	1	Negative	1,7 %
		>>>	1	Positive	1,7 %
----- Total per sample: n = 60		----- Success: 98 %			
Total success: 98 %					

(464) anti-cardiolipin IgM

A	(5) Dialab	>>>	1	Negative	1,7 %
	(14) Bio-Rad	>>>	1	Negative	1,7 %
	(38) IL	>>>	3	Negative	5,1 %
	(49) BioVendor	>>>	1	Negative	1,7 %
	(87) Euroimmun	>>>	6	Negative	10 %
	(115) BioSystems	>>>	1	Negative	1,7 %
	(135) OrgenTec	>>>	21	Negative	36 %
	(139) BL Diagnostics	>>>	1	Negative	1,7 %
	(148) Aesku.lab Diagnostika	>>>	7	Negative	12 %
	(166) Thermo Fisher	>>>	4	Negative	6,8 %
	(183) Immunodiagnostic Systems	>>>	2	Negative	3,4 %
	(211) INOVA Diagnostics	>>>	9	Negative	15 %
	(999) another manufacturer	>>>	2	Negative	3,4 %
----- Total per sample: n = 59		----- Success: 100 %			
B	(5) Dialab	>>>	1	Negative	1,7 %
	(14) Bio-Rad	>>>	1	Negative	1,7 %
	(38) IL	>>>	3	Negative	5,1 %
	(49) BioVendor	>>>	1	Negative	1,7 %
	(87) Euroimmun	>>>	6	Negative	10 %
	(115) BioSystems	>>>	1	Negative	1,7 %
	(135) OrgenTec	>>>	21	Negative	36 %
	(139) BL Diagnostics	>>>	1	Negative	1,7 %

Summary statistics - qualitative results

(Groups: manufacturer of kit)

EQA round: APLA2/21 - Antiphospholipid Antibodies

Deadline: 01.10.2021

Test						
Sample	Group		N	Result	N _{rel}	
B	(148) Aesku.lab Diagnostika	>>>	7	Negative	12 %	
	(166) Thermo Fisher	>>>	4	Negative	6,8 %	
	(183) Immunodiagnostic Systems	>>>	2	Negative	3,4 %	
	(211) INOVA Diagnostics	>>>	9	Negative	15 %	
	(999) another manufacturer	>>>	2	Negative	3,4 %	
	Total per sample: n = 59		Success: 100 %			
Total success: 100 %						
(465) anti-beta2-GP 1 screening						
A	(5) Dialab	>>>	1	Negative	7,1 %	
	(38) IL	>>>	1	Negative	7,1 %	
	(49) BioVendor	>>>	1	Negative	7,1 %	
	(135) OrgenTec	>>>	9	Negative	64 %	
	(148) Aesku.lab Diagnostika	>>>	2	Negative	14 %	
	Total per sample: n = 14		Success: 100 %			
B	(5) Dialab	>>>	1	Positive	7,1 %	
	(38) IL	>>>	1	Positive	7,1 %	
	(49) BioVendor		1	Inconclusive result (borderline)	7,1 %	
	(135) OrgenTec	>>>	9	Positive	64 %	
	(148) Aesku.lab Diagnostika		1	Negative	7,1 %	
			>>>	1	Positive	7,1 %
Total per sample: n = 14		Success: 86 %				
Total success: 86 %						
(467) anti-beta2-GP 1 IgG						
A	(14) Bio-Rad	>>>	1	Negative	1,8 %	
	(38) IL	>>>	4	Negative	7,3 %	
	(87) Euroimmun	>>>	6	Negative	11 %	
	(135) OrgenTec	>>>	20	Negative	36 %	
	(139) BL Diagnostics	>>>	1	Negative	1,8 %	
	(148) Aesku.lab Diagnostika	>>>	6	Negative	11 %	
	(166) Thermo Fisher	>>>	4	Negative	7,3 %	
	(183) Immunodiagnostic Systems	>>>	1	Negative	1,8 %	
	(211) INOVA Diagnostics	>>>	10	Negative	18 %	
	(999) another manufacturer	>>>	2	Negative	3,6 %	
Total per sample: n = 55		Success: 100 %				
B	(14) Bio-Rad	>>>	1	Positive	1,8 %	
	(38) IL	>>>	4	Positive	7,3 %	
	(87) Euroimmun	>>>	6	Positive	11 %	
	(135) OrgenTec	>>>	20	Positive	36 %	
	(139) BL Diagnostics	>>>	1	Positive	1,8 %	
	(148) Aesku.lab Diagnostika		5	Negative	9,1 %	
			>>>	1	Positive	1,8 %
	(166) Thermo Fisher	>>>	4	Positive	7,3 %	
	(183) Immunodiagnostic Systems	>>>	1	Positive	1,8 %	
	(211) INOVA Diagnostics		1	Negative	1,8 %	
			>>>	9	Positive	16 %
(999) another manufacturer		1	Negative	1,8 %		
		>>>	1	Positive	1,8 %	
Total per sample: n = 55		Success: 87 %				
Total success: 87 %						
(468) anti-beta2-GP 1 IgM						
A	(14) Bio-Rad	>>>	1	Negative	1,9 %	
	(38) IL	>>>	4	Negative	7,4 %	
	(87) Euroimmun	>>>	5	Negative	9,3 %	
	(135) OrgenTec	>>>	20	Negative	37 %	
	(139) BL Diagnostics	>>>	1	Negative	1,9 %	
	(148) Aesku.lab Diagnostika	>>>	6	Negative	11 %	
	(166) Thermo Fisher	>>>	4	Negative	7,4 %	
	(183) Immunodiagnostic Systems	>>>	1	Negative	1,9 %	
	(211) INOVA Diagnostics	>>>	10	Negative	19 %	
(999) another manufacturer	>>>	2	Negative	3,7 %		
Total per sample: n = 54		Success: 100 %				
B	(14) Bio-Rad	>>>	1	Negative	1,9 %	
	(38) IL	>>>	4	Negative	7,4 %	
	(87) Euroimmun	>>>	5	Negative	9,3 %	
	(135) OrgenTec	>>>	20	Negative	37 %	
	(139) BL Diagnostics	>>>	1	Negative	1,9 %	
	(148) Aesku.lab Diagnostika	>>>	6	Negative	11 %	

Summary statistics - qualitative results

(Groups: manufacturer of kit)

EQA round: APLA2/21 - Antiphospholipid Antibodies

Deadline: 01.10.2021

Test					
Sample	Group		N	Result	N _{rel}
B	(166) Thermo Fisher	>>>	4	Negative	7,4 %
	(183) Immunodiagnostic Systems	>>>	1	Negative	1,9 %
	(211) INOVA Diagnostics	>>>	10	Negative	19 %
	(999) another manufacturer	>>>	2	Negative	3,7 %
Total per sample: n = 54			Success: 100 %		
Total success: 100 %					

st_kl

End of report

Printed: 06.10.2021